Pemvidutide (ALT-801) Dosing Protocol: 1:1 GLP-1/Glucagon Guide
Also known as: ALT-801, Altimmune 1:1 GLP-1/Glucagon Agonist
Studied in published research — not a medical recommendation. Primary protocol (MOMENTUM Phase 2b Obesity & Lean-Preservation Protocol): 1.2 mg or 1.8 mg weekly (no titration) or 2.4 mg weekly (after 4-week ramp), Once weekly.
Once weekly
Research-reported range (no primary dosing study). 2.4 mg dose achieved 15.6% mean weight loss at 48 weeks with 78.1% of weight loss derived from fat tissue
Subcutaneous injection
Human clinical trials or FDA-approved formulation exists
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 4 doses in the vial at the low end (2 doses at the high end).
Save Pemvidutide to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a GLP-1 Agonist?
A molecule that mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, slows gastric emptying, and reduces appetite. Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are GLP-1 agonists. These are peptides, but they are marketed and prescribed as pharmaceutical drugs.
Bottom Line Up Front
Pemvidutide (ALT-801) is a balanced 1:1 GLP-1/Glucagon dual receptor agonist by Altimmune. Phase 2b MOMENTUM showed 15.6% weight loss at 48 weeks with 78.1% of weight lost from adipose tissue (only 21.9% lean mass), plus 68.5% liver fat reduction in the IMPACT MASH trial.
Hepatic fat clearance (MASH) and obesity weight loss with superior lean muscle preservation
Glycemic HbA1c reduction in severe insulin-dependent Type 2 diabetes vs pure GIP/GLP-1 agonists
ALT-801 (Altimmune — Investigational Phase 2b/3)
3 (0 human)
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Pemvidutide is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
Pemvidutide is a 29-amino-acid peptide engineered with an equimolar (1:1) potency ratio at human GLP-1 and Glucagon receptors, conjugated to a proprietary glycolipid surfactant domain that slows subcutaneous absorption and binds serum albumin. Because its absorption profile avoids sharp Cmax spikes, Pemvidutide can be administered at 1.2 mg and 1.8 mg weekly without multi-month dose titration, while closely mimicking the physiological metabolic effects of endurance exercise and ketogenic fat oxidation.
Mechanisms of Action
- 1:1 balanced agonism at GLP-1R (central satiety & caloric reduction) and GCGR (hepatic beta-oxidation & thermogenesis)
- EuPort glycolipid surfactant attachment slows peak plasma Cmax after SubQ injection, improving tolerability without mandatory titration at 1.2–1.8 mg
- Preserves skeletal muscle mass during caloric deficit: MRI body-composition sub-studies showed 78.1% fat mass loss vs only 21.9% lean mass reduction
- Directly mobilizes intrahepatic triglycerides, reducing liver fat by up to 68.5% by MRI-PDFF within 24 weeks
Research Protocols
Summaries of published research. For educational purposes only.
| Protocol Name | Source | Dose | Frequency | Duration | Route | Evidence | Link | Save |
|---|---|---|---|---|---|---|---|---|
| MOMENTUM Phase 2b Obesity & Lean-Preservation Protocol | reported protocol | 1.2 mg or 1.8 mg weekly (no titration) or 2.4 mg weekly (after 4-week ramp) | Once weekly | 24–48 weeks | Subcutaneous injection | clinical trial | — |
Metabolic, Hepatic & Incretin Safety Biomarker Panel (Pemvidutide)
Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.
HbA1c & Fasting Insulin (HOMA-IR)
Day 0 + Wk 6–8Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.
Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.
ALT, AST & GGT Liver Enzymes
Day 0 + Wk 6–8Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.
Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.
ApoB, Triglycerides & Advanced Lipid Panel
Day 0 + Wk 6–8Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.
Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.
Serum Lipase, Amylase & eGFR / Cystatin C
Day 0 + Wk 6–8Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.
Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Investigational Phase 2b/3 compound — not yet FDA approved
- •Ensure adequate dietary protein (1.6–2.0 g/kg/day) and electrolyte intake to support hepatic ketogenesis and lean mass retention
- •Monitor ALT/AST, fasting glucose, and resting heart rate at baseline and week 6–8
Where to get Pemvidutide, baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Related Peptides
More metabolic peptides
Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the horm...
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It rep...
Retatrutide
Retatrutide is a triple hormone receptor agonist developed b...
Liraglutide
Liraglutide is an FDA-approved GLP-1 receptor agonist used f...
AOD-9604 (hGH Frag 176-191)
AOD-9604 is a modified fragment of human growth hormone (hGH...
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.